About BRC Therapeutics
BRC Therapeutics is a Healthcare company based in Monterey (United States) founded in 2017. Research and manufacturing of hemp products are conducted by BRC. It operates on a HealthTech model. BRC Therapeutics has raised $25.26 million across 4 funding rounds from investors including Argonautic, Intrinsic Capital Partners and Achari Ventures. The company has 16 employees. BRC Therapeutics offers products and services including CRPS Therapeutic Candidate and AIIA Therapeutic Candidate. Its focus areas include Biotechnology and Therapeutics. Its legal entity is Biopharmaceutical Research Company.
Company details
BRC Therapeutics is engaged in the development of innovative therapeutics aimed at providing relief from pain and other symptoms in acute and chronic conditions. The company has established a pipeline of prescription medicines based on cannabinoids, targeting pain, neurological, and inflammatory conditions. Two investigational products are currently under clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). The organization is committed to creating multimodal therapeutics designed for safety and efficacy, ensuring patient comfort. BRC operates as a fully integrated entity, driving innovation from development through to commercialization within the regulated cannabinoid therapeutics sector.
- Headquarters Monterey, United States
- Employees 16
- SectorsHealthcare
- Website biopharmaresearchco.com
- Social LinkedIn
- Legal Name Biopharmaceutical Research Company
- Total Equity Funding$25.26M (USD)
in 4 rounds
- Latest Funding Round$676.07K (USD), Series A
Aug 2023
- InvestorsArgonautic
& 5 more
- Employee Count16
Products & Services of BRC Therapeutics
BRC Therapeutics offers a comprehensive portfolio of products and services, including CRPS Therapeutic Candidate and AIIA Therapeutic Candidate.
Therapeutic candidate tested for Complex Regional Pain Syndrome.
Therapeutic candidate tested for Aromatase Inhibitor-Induced Arthralgia.
Funding Insights of BRC Therapeutics
BRC Therapeutics has successfully raised a total of $25.26M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $676.07 thousand completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.26M
- Total Rounds 4
- Last Round Series A — $676,065
- First Round $2.05M
(Oct 2020)
- Investors Count 6
All 4 funding rounds of BRC Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $676,065 | Series A | – | – | – |
| Jul 2022 | $20M | Series A | – | Intrinsic Capital Partners | |
| Mar 2022 | $2.54M | Seed | – | – | – |
| Oct 2020 | $2.05M | Seed | – | – | – |
6 investors in total: 6 institutional.
Investors in BRC Therapeutics
BRC Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Argonautic, Intrinsic Capital Partners and Achari Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about Intrinsic Capital Partners. | intrinsiccapitalpartners.com | |||
Achari Ventures is engaged in investment across niche industries. | acharivc.com | |||
Growth equity investments are made in hyper-growth markets by AFI Capital Partners. | aficapitalpartners.com | California, United States | ||
| deltaemerald.com | ||||
A global macro multi-asset hedge fund focused on strategic investments and portfolio management. | 2016 | argonauticventures.com | George Town, Cayman Islands | |
| selfhealthamerica.tcc.mode |
Investor details for BRC Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BRC Therapeutics
7 people are tracked at BRC Therapeutics (6 in leadership, 1 in team); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Lucas Zumstein | Vice President Operations | Leadership |
George Hodgin | Chief Executive Officer | Leadership |
David Weinmann | Vice President of Finance | Leadership |
Kyle Ruddy | Director of Production | Leadership |
Brian Brandley | Laboratory Director | Leadership |
Laura Deshullo | Director Of Program Management, CMC | Leadership |
Spencer Little | Lead Scientist | Team |
Complete people profiles for BRC Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BRC Therapeutics
3 dated milestones of BRC Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded BRC Therapeutics is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series A, of $676K.
Top companies in Clinical Trials & Research Tech
3 companies that operate in the same segment as BRC Therapeutics (Clinical Trials & Research Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 619.8 M | 252 | ||
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | 22 | ||
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | 25 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BRC Therapeutics
BRC Therapeutics was founded in 2017 and raised its 1st funding round 3 years after it was founded.
BRC Therapeutics is headquartered in Monterey, United States. It is registered at Monterey, California, United States.
BRC Therapeutics is a funded company, having raised a total of $25.26M across 4 funding rounds to date. The company's 1st funding round was a Seed of $2.05M, raised on Oct 2020.
BRC Therapeutics has 16 employees.
BRC Therapeutics is engaged in the development of innovative therapeutics aimed at providing relief from pain and other symptoms in acute and chronic conditions. The company has established a pipeline of prescription medicines based on cannabinoids, targeting pain, neurological, and inflammatory conditions. Two investigational products are currently under clinical trials for Complex Regional Pain Syndrome (CRPS) and Aromatase Inhibitor-Induced Arthralgia (AIIA). The organization is committed to creating multimodal therapeutics designed for safety and efficacy, ensuring patient comfort. BRC operates as a fully integrated entity, driving innovation from development through to commercialization within the regulated cannabinoid therapeutics sector.
BRC Therapeutics offers CRPS Therapeutic Candidate and AIIA Therapeutic Candidate.
BRC Therapeutics has 6 investors. Key investors include Argonautic, Intrinsic Capital Partners, Achari Ventures, AFI Capital Partners, and Delta Emerald Ventures.
BRC Therapeutics operates through Biopharmaceutical Research Company.